Opinion|Videos|October 20, 2023

Treatment Considerations for Ponatinib in Patients With CML

Author(s)Andrew Kin, MD, Jeffrey Zonder, MD, Craig Cole, MD

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Episodes in this series

The host of Cancer Network's Face-Off program shown with an introductory slide

EP. 1 Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

EP. 2 Ponatinib Dose-Ranging Data in Chronic-Phase CML

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

EP. 3 Treatment Considerations for Ponatinib in Patients With CML

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

EP. 4 Olverembatinib in Patients with Pretreated/Refractory CML

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

EP. 5 Potential Role of Olverembatinib in CML

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

EP. 6 ASCEMBL: Recent Data Updates for Asciminib in CML

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

EP. 7 Clinical Applications for Asciminib in CML

John Molina, MD, MEd, an expert on chronic myeloid leukemia

EP. 8 OPTIC Trial: 3-Year Data Update in CML

EP. 9 Treatment Updates and Key Highlights in Multiple Myeloma and CML

EP. 9 Treatment Updates and Key Highlights in Multiple Myeloma and CML

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.

October 2nd, 2026

FDA OKs Pirtobrutinib in Frontline CLL/SLL

The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

September 28th, 2026

Pirtobrutinib Earns Approval in China for CLL/SLL Across All Therapy Lines

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

Trending on CancerNetwork

Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma

How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

FDA OKs Pirtobrutinib in Frontline CLL/SLL

NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC